Extracellular polymeric substances production (EPS production)

Extracellular polymeric substances (EPS) production refers to the complex biosynthetic process through which microorganisms—primarily bacteria and fungi—synthesize and secrete a matrix composed of polysaccharides, proteins, lipids, and extracellular DNA (eDNA). This self-produced matrix is the hallmark of the biofilm lifestyle, providing the structural integrity required for microbial communities to adhere to surfaces and to one another. EPS serves as a protective barrier that shields embedded pathogens from the host immune system and significantly limits the penetration of antimicrobial agents, contributing to the high levels of antibiotic tolerance observed in chronic infections. Clinically, EPS production is a major virulence factor in conditions such as cystic fibrosis, where Pseudomonas aeruginosa-produced alginate leads to persistent lung colonization, and in dental caries and medical device-associated infections. Therapeutic strategies targeting EPS production aim to weaken the biofilm architecture to enhance antibiotic efficacy. These include the use of degradative enzymes like dornase alfa (DNase I) to target eDNA, alginate lyase, and dispersin B to hydrolyze specific polysaccharides, as well as quorum-sensing inhibitors that disrupt the regulatory signaling pathways responsible for initiating polymer synthesis.

Other names

Biofilm matrix productionExopolysaccharide productionEPS biosynthesisExtracellular matrix productionExtracellular polymeric substances synthesis

Disruption of biofilm structural integrity through the enzymatic hydrolysis of matrix polymers (e.g., eDNA, polysaccharides) or the pharmacological inhibition of regulatory signaling networks, such as quorum sensing, that govern the synthesis and secretion of extracellular polymers.